A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid MalignanciesCurtis A. Lachowiez, Courtney D. DiNardo, Sanam Loghavi et al.|Blood Cancer Discovery|2023Cited by 122
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinomaXiaochao Tan, Jonathan M. Kurie, Priyam Banerjee et al.|Science Translational Medicine|2020Cited by 68
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Clinical Cancer Research|2024Cited by 42
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC NetworkZexian Zeng, Catherine J. Wu, Jingxin Fu et al.|Clinical Cancer Research|2020Cited by 15
Cobimetinib plus atezolizumab for <i>RAS</i> and <i>NF</i>1/2-mutated poorly differentiated thyroid carcinoma.Sarah Hamidi, Ramona Dadu, Naifa L. Busaidy et al.|Journal of Clinical Oncology|2024Cited by 4